Dupixent Delivers… and Sanofi-Regeneron Ushers in a New Era of Atopic Dermatitis (AD) Treatment

According to Spherix Global Insights, at just one month post-launch, nearly one-third of surveyed dermatologists (n=101) have prescribed Dupixent, although for some a burdensome reimbursement process is slowing the time from prescription to fulfillment. Download Report Overview EXTON, Pa., May 17, 2017 /PRNewswire/ -- According to the latest RealTime Dynamix™: Atopic Dermatitis report, just one

Novartis’ Cosentyx Takes the Wind Out of Stelara’s Sails in Psoriatic Arthritis Market

New findings in a recent study by Spherix Global Insights, RealWorld Dynamix™: Biologic and Otezla Switching in PsA, indicate an increased rate of switching to the brand and strong momentum for Cosentyx compared to previous results collected in November 2015 Download Report Overview EXTON, Pa., May 16, 2017 /PRNewswire/ -- A recent patient chart analysis

Roche’s Ocrevus: Penetrating Beyond Progressive MS

Recent analysis of over 2,000 patient charts indicates Ocrevus will present a challenge to other disease-modifying therapies (DMTs) in the RRMS segment as well as the PPMS segment, according to new data released by Spherix Global Insights. EXTON, Pa., May 12, 2017 /PRNewswire/ -- The future landscape of the DMT market is embedded in the

Keryx’s Auryxia and Vifor-FMC’s Velphoro Slowly Gaining Share in the Phosphate Binder Market While Big Shifts in CKD-MBD Loom With the Pending Introduction of Amgen’s Parsabiv

Over 300 US nephrologists and renal dietitians (RD) describe future practice pattern changes in most recent quarterly update by Spherix Global Insights. Download Report Overview EXTON, Pa., May 10, 2017 /PRNewswire/ -- In a market long dominated by Sanofi-Genzyme's Renvela, there are signs that the newer non-calcium, iron-based binders (Keryx's Auryxia and Vifor-FMC's Velphoro) are

EU Rheumatoid Arthritis Landscape Poised for Big Changes as Rheumatologists Plan for the Adoption of Eli Lilly/Incyte’s Olumiant, Pfizer’s Xeljanz, and Regeneron/Sanofi’s Kevzara

With the recent approval of two new JAK inhibitors and the imminent introduction of additional IL-6 inhibitors, EU rheumatologists anticipate substantial practice shifts in RA management. Download Report Overview EXTON, Pa., May 4, 2017 /PRNewswire/ -- Spherix Global Insights recently released data collected from 257 rheumatologists in France, Germany, Italy, Spain and the UK, revealing